Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 3/2018

01-09-2018 | Risk and Prevention (ME Wood, Section Editor)

Management of Lobular Neoplasia

Authors: Freya R. Schnabel, Jessica C. Gooch, Jennifer Chun

Published in: Current Breast Cancer Reports | Issue 3/2018

Login to get access

Abstract

Purpose of Review

Lobular neoplasia (LN) is a well-established risk factor and non-obligate precursor for breast cancer. The clinical breast cancer risk assessment and management for these patients can be challenging.

Recent Findings

Numerous studies have confirmed that LN is a risk factor and non-obligate precursor for breast cancer. The molecular profile of LCIS is similar to invasive lobular carcinoma. Surgical excision is generally recommended after core biopsy, but there may be a subset of patients with LN who may be observed without surgery. The significant increase in breast cancer risk associated with this disease justifies close surveillance. Chemoprevention is beneficial but uptake remains a challenge.

Summary

This paper is a review of the historical and contemporary studies on the clinicopathologic characteristics of LN, the associated risk of breast cancer development, and current management of patients with lobular neoplasia.
Literature
1.
Khoury T, Karabakhtsian RG, Mattson D, Yan L, Syriac S, Habib F, et al. Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases. Histopathology. 2014;64(7):981–93.
2.
Clauser P, Marino MA, Baltzer PA, Bazzocchi M, Zuiani C. Management of atypical lobular hyperplasia, atypical ductal hyperplasia, and lobular carcinoma in situ. Expert Rev Anticancer Ther. 2016;16(3):335–46.CrossRefPubMed
3.
Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42:737–69.CrossRefPubMed
4.
5.
Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290–303.
6.
Jorns J, Sabel MS, Pang JC. Lobular neoplasia: morphology and management. Arch Pathol Lab Med. 2014;138:1344–9.CrossRefPubMed
7.
Susnik B, Day D, Abeln E, Bowman T, Krueger J, Swenson KK, et al. Surgical outcomes of lobular neoplasia diagnosed in core biopsy: prospective study of 316 cases. Clin Breast Cancer. 2016;16(6):507–13.
8.
Calhoun BC, Collie AM, Lott-Limbach AA, Udoji EN, Sieck LR, Booth CN, et al. Lobular neoplasia diagnosed on breast core biopsy: frequency of carcinoma on excision and implications for management. Ann Diagn Pathol. 2016;25:20–5.
9.
Portschy PR, Marmor S, Nzara R, Virnig BA, Tuttle TM. Trends in incidence and management of lobular carcinoma in situ: a population-based analysis. Ann Surg Oncol. 2013;20(10):3240–6.CrossRefPubMed
10.
Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast—risk assessment and management options. N Engl J Med. 2015;372(1):78–89.CrossRefPubMedPubMedCentral
11.
Hartmann LC, Radisky DC, Frost MH, Santen RJ, Vierkant RA, Benetti LL, et al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila). 2014;7(2):211–7.
12.
Vierkant RA, Degnim AC, Radisky DC, Visscher DW, Heinzen EP, Frank RD, et al. Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort. BMC Cancer. 2017;17(1):84.
13.
McCart Reed AE, Kutasovic JR, Lakhani SR, Simpson PT. Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. Breast Cancer Res. 2015;17:12.CrossRefPubMed
14.
Racz JM, Carter JM, Degnim AC. Lobular neoplasia and atypical ductal hyperplasia on core biopsy: current surgical management recommendations. Ann Surg Oncol. 2017;24(10):2848–54.CrossRefPubMed
15.
16.
Wallace AS, Xiang D, Hockman L, Arya M, Jeffress J, Wang Z, et al. Synchronous lobular carcinoma in situ and invasive lobular cancer: marker or precursor for invasive lobular carcinoma. Eur J Surg Oncol. 2014;40(10):1245–9.
17.
18.
Dunderdale J, Khan SA. Lobular neoplasia: another reset in management? Ann Surg Oncol. 2016;23(3):706–7.CrossRefPubMed
19.
Nakhlis F, Gilmore L, Gelman R, Bedrosian I, Ludwig K, Hwang ES, et al. Incidence of adjacent synchronous invasive carcinoma and/or ductal carcinoma in-situ in patients with lobular neoplasia on core biopsy: results from a prospective multi-institutional registry (TBCRC 020). Ann Surg Oncol. 2016;23:722–8.
20.
Allen S, Levine EA, Lesko N, Howard-McNatt M. Is excisional biopsy and chemoprevention warranted in patients with atypical lobular hyperplasia on core biopsy? Am Surg. 2015;81:876–8.PubMed
21.
Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Lobular carcinoma in situ of the female breast: short-term results of a prospective nationwide study. Am J Surg Pathol. 1993;17(1):14–21.CrossRefPubMed
22.
23.
Chester R, Bokinni O, Ahmed I, Kasem A. Systematic literature review of breast lobular carcinoma in situ (LCIS) risk of future malignancy and management. Eur J Surg Oncol. 2014;40(5):614.CrossRef
24.
McEvoy MP, Coopey SB, Mazzola E, Buckley J, Belli A, Polubriaginof F, et al. Breast cancer risk and follow-up recommendations for young women diagnosed with atypical hyperplasia and lobular carcinoma in situ (LCIS). Ann Surg Oncol. 2015;22(10):3346–9.CrossRefPubMed
25.
Renshaw AA, Gould EW. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies. Pathology. 2016;48(1):25–9.CrossRefPubMed
26.
King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol. 2015;33(33):3945–52.
27.
Degnim AC, Dupont WD, Radisky DC, Vierkant RA, Frank RD, Frost MH, et al. Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer. 2016;122(19):2971–8.
28.
Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136(3):627–33.CrossRefPubMed
29.
Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. 2007;25(19):2671–7.
30.
Degnim AC, Visscher DW, Radisky DC, Frost MH, Vierkant RA, Frank RD, et al. Breast cancer risk by the extent and type of atypical hyperplasia. Cancer. 2016;122(19):3087–8.
31.
32.
Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. J Am Med Assoc. 2012;307(13):1394–404.
33.
Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(23):2942–62.
34.
Roetzheim RG, Lee JH, Fulp W, Matos Gomez E, Clayton E, Tollin S, et al. Acceptance and adherence to chemoprevention among women at increased risk of breast cancer. Breast. 2015;24(1):51–6.
35.
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–62.
36.
Vogel VG 3rd, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–41.CrossRefPubMed
37.
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah MT, Cronin WM, et al. Tamoxifen for prevention of breast Cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.
38.
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041–8.
39.
Richardson H, Johnston D, Pater J, Goss P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol. 2007;14(3):89–95.CrossRefPubMedPubMedCentral
40.
Goss P, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91.CrossRefPubMed
41.
Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12(5):496–503.
42.
Metadata
Title
Management of Lobular Neoplasia
Authors
Freya R. Schnabel
Jessica C. Gooch
Jennifer Chun
Publication date
01-09-2018
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 3/2018
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-018-0284-9

Other articles of this Issue 3/2018

Current Breast Cancer Reports 3/2018 Go to the issue

Risk and Prevention (ME Wood, Section Editor)

Lifestyle Interventions for Breast Cancer Prevention

Global Breast Cancer (BO Anderson and C Duggan, Section Editors)

Breast Cancer Diagnosis and Treatment in Low- and Mid-Resource Settings: the Role of Resource-Stratified Clinical Practice Guidelines

Global Breast Cancer (BO Anderson and C Duggan, Section Editors)

Early Diagnosis of Breast Cancer in the Absence of Population-Based Mammographic Screening in Asia

Risk and Prevention (ME Wood, Section Editor)

Risk and Prevention for Highly Penetrant Genes

Risk and Prevention (ME Wood, Section Editor)

Breast Reconstruction in the Setting of Surgical Prevention for Breast Cancer

Global Breast Cancer (BO Anderson and C Duggan, Section Editors)

Access to Affordable Breast Cancer Care in Eastern Europe
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits